|Bid||0.00 x 100|
|Ask||4,378.00 x 100|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||15.84|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.
Millions of Americans are eagerly waiting to find out how much their Social Security cost-of-living adjustment (COLA) will be for 2023. One big reason why that's the case is that Social Security's COLA calculation doesn't include Medicare Part B premiums. You might wonder how Medicare Part B premiums could possibly decline.
Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.